title: Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
abstract: OBJECTIVE
  The influence of androgen deprivation therapy (ADT) on (11)C-choline uptake in patients with prostate cancer (PC) has not yet been clarified. The aim of our study was to investigate this issue by means of sequential (11)C-choline positron emission tomography (PET)/CT in patients with recurrent PC.
  
  
  METHODS
  We retrospectively studied 14 recurrent PC patients (mean age 67 years, range 55-82) during follow-up after radical prostatectomy (RP) with rising serum prostate-specific antigen (PSA) levels. All patients had undergone at least two consecutive (11)C-choline PET/CT scans: the first (11)C-choline PET/CT before commencing ADT and the second (11)C-choline PET/CT after 6 months of ADT administration.
  
  
  RESULTS
  The mean serum PSA level before ADT was 17.0 ± 44.1 ng/ml. After 6 months of ADT administration the PSA value significantly decreased in comparison to baseline (PSA = 2.4 ± 3.1 ng/ml, p < .025). Moreover, before starting ADT, 13 of 14 patients had positive (11)C-choline PET/CT for metastatic spread, while after 6 months of ADT administration in 9 of 14 patients (11)C-choline PET/CT became negative.
  
  
  CONCLUSIONS
  These preliminary results suggest that ADT significantly reduces (11)C-choline uptake in androgen-sensitive PC patients.
authors: Department of Nuclear Medicine, PAD. 30, Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. chiara.fuccio@libero.it
authors: Chiara
authors: C
authors: Fuccio
authors: Riccardo
authors: R
authors: Schiavina
authors: Paolo
authors: P
authors: Castellucci
authors: Domenico
authors: D
authors: Rubello
authors: Giuseppe
authors: G
authors: Martorana
authors: Monica
authors: M
authors: Celli
authors: Claudio
authors: C
authors: Malizia
authors: Marta Barios
authors: MB
authors: Profitos
authors: Maria Cristina
authors: MC
authors: Marzola
authors: Vincenzina
authors: V
authors: Pettinato
authors: Stefano
authors: S
authors: Fanti
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism*; D000813:Anilides / Q000494:pharmacology / Q000627:therapeutic use; D001692:Biological Transport / Q000187:drug effects; D002250:Carbon Radioisotopes; D002794:Choline / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D015999:Multivariate Analysis; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism*; D012008:Recurrence; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D014105:Tosyl Compounds / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D000813:Anilides; D002250:Carbon Radioisotopes; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D002794:Choline